Nipro (TSE:8086) Pulls Back, But Does The Valuation Story Still Hold?

Nipro (TSE:8086) slipped to ¥1,443 at the latest close, with the share price down about 7% over the past month and roughly 12% over the past 3 months.

The recent 1 month share price return of about 8% in the red fits into a softer trend for Nipro, with the year to date share price return also slightly negative, while the 1 year total shareholder return has slipped about 5%. However, the 3 and 5 year total shareholder returns remain firmly positive in the 20% to 35% range. This suggests that current weakness reflects a cooler mood on near term prospects rather than a break in the longer run story.

Scan beyond Nipro's recent pullback and size up other hand picked healthcare stocks with resilient balance sheets and fundamentals through our list of solid balance sheet and fundamentals (20 results).

Nipro now trades well below analyst targets after this pullback. The gap looks tempting on paper. The real test is whether the market’s caution aligns with the company’s fundamentals.

Price-to-Earnings of 17x for Nipro: Is it justified?

Nipro trades on a P/E of roughly 17x, which lines up closely with the Japan medical equipment industry on 17.3x and still sits below the estimated fair P/E of 20.1x. At ¥1,443, the market is not paying a clear premium for the recent rebound in earnings.

The P/E ratio compares the share price with earnings per share, so it reflects how much investors are willing to pay for each unit of profit. For a diversified healthcare supplier like Nipro, this metric links directly to expectations around future profitability and the stability of demand for its devices, pharmaceuticals, and packaging business.

Forecast earnings growth of around 12% per year, compared with the wider Japan market at 8.8%, indicates that investors are not necessarily overpaying for projected profit expansion at this P/E level. Net income growth of 120.3% year on year, together with profit margins moving from 0.9% to 2.1%, points to a business that has recently changed its earnings profile, even if Return on Equity of 4.8% remains low and is projected to stay below 10% over the next three years.

The comparison to peers is important. Nipro trades on a P/E that is slightly below both the medical equipment sector average of 17.3x and the peer group average of 18.7x, while the estimated fair P/E is higher at 20.1x. The market is applying a discount relative to both the sector and the fair ratio level that it could theoretically converge toward if earnings quality and balance sheet concerns ease.

Explore the SWS fair ratio for Nipro.

Result: Price-to-Earnings of 17x (UNDERVALUED).

Still, the recent share price weakness and relatively low Return on Equity suggest that any disappointment in profit trends could quickly erode confidence in the Nipro story.

Find out about the key risks to this Nipro narrative.

Another View on Nipro’s Value

The P/E story paints Nipro as modestly priced. A different lens tells a sharper story. Our DCF model points to a future cash flow value of about ¥995.21 per share, which sits well below the current ¥1,443 level, so on this measure the stock screens as overvalued. Which signal do you trust when they point in opposite directions?

For readers who want to see how this cash flow view is built line by line, and how sensitive it is to the inputs that sit behind it, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nipro for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 17 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around Nipro’s valuation and growth can feel messy. Check the numbers yourself, weigh the upside against the weak spots, and use the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Nipro?

If Nipro has sharpened your thinking on price and quality, do not stop there. Broaden your watchlist with other ideas that share clear, data backed stories.

• Hunt for potential mispricings by scanning companies that screen as high quality bargains through the 17 high quality undervalued stocks.
• Strengthen your income stream by reviewing businesses that feature the 14 dividend fortresses.
• Dial down risk by focusing on resilient balance sheets and fundamentals using the 21 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com